TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06211881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chi-GVM
Description: Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle.
Study: NCT04743115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS HH 002.SA
Description: The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL
Study: NCT05444556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally.
Study: NCT05086185

Intervention type: DIAGNOSTIC_TEST
Intervention: Kalemic Response to Orange Juice
Description: 100% pulp-free orange juice

Intervention type: DIETARY_SUPPLEMENT
Intervention: Kalemic Response to Orange Juice with Fiber
Description: 100% pulp-free orange juice with psyllium-based fiber added
Study: NCT06064630

Intervention type: DEVICE
Group type: OTHER
Intervention: Automatic continuous positive airway pressure
Description: Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea

Intervention type: DEVICE
Group type: OTHER
Intervention: Automatic continuous positive airway pressure
Description: Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
Study: NCT05633563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Oral intake of capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of capsules
Study: NCT05774535

Intervention type: OTHER
Intervention: Experimental
Description: Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~* informed consent;~* personal data and medical records;~* registration of medical therapy and post-procedural pharmacological protocol~* surgical check;~* supra-aortic trunks EchocolorDoppler;~* pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~* surgical checks;~* registration of drug therapy;~* recording of all adverse events that occurred during hospitalization~* supra-aortic trunks EchocolorDoppler and cIMT measurement;~* blood sampling.
Study: NCT04608981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Description: Steroidal anti-inflammatory drug as a preoperative medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50mg Tab
Description: Non-steroidal anti-inflammatory drug as a preoperative medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study: NCT04129593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Awakening - Natural Waking
Description: subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snooze - Natural waking
Description: subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
Study: NCT04907682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin iv
Description: 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
Study: NCT06405360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg consumption
Description: Participants in the intervention group will be provided two eggs to consume daily.
Study: NCT05306964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive UFnet Rate Strategy
Description: In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liberal UFnet Rate Strategy
Description: In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
Study: NCT06062654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-assisted Rehabilitation
Description: Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-assisted Rehabilitation
Description: Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Rehabilitation
Description: Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Rehabilitation
Description: Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
Study: NCT04777617

Intervention type: OTHER
Intervention: DD-cfDNA
Description: We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study

Intervention type: OTHER
Intervention: DD-cfDNA
Description: We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
Study: NCT04467749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension Wheel
Description: Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
Study: NCT05588856

Intervention type: OTHER
Intervention: In depth Interview
Description: In depth Interviews

Intervention type: OTHER
Intervention: In depth Interview
Description: In depth Interviews
Study: NCT06076681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
Study: NCT04026464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Ibuprofen
Description: The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ibuprofen + Oral Acetaminophen
Description: The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
Study: NCT05342961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinous balloon dilatation catheter (Plastic-Blade)
Description: To treat Coronary artery disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinous balloon dilatation catheter(lacrosse NSE)
Description: To treat Coronary artery disease
Study: NCT06417840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)
Description: N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (\>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study: NCT05104281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib oral and bevazizumab intravenously
Description: osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
Study: NCT06255327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I COUGH care program
Description: The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees.
Study: NCT05363371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minds and Mentors
Description: Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Twelve Step Intervention Group
Description: Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
Study: NCT04936607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized hydration strategy
Description: In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
Study: NCT06239584

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsies performed via bronchoscopy
Description: An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
Study: NCT04903561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColliPee
Description: The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
Study: NCT05946655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin + Metronidazole
Description: Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
Study: NCT05164081

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
Description: Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
Description: antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
Study: NCT05529498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate paced continuous gait training
Description: walking continuously for 20 minutes at a moderate pace

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval gait training
Description: 20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
Study: NCT04853758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
Study: NCT05569434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
Study: NCT06544174

Intervention type: OTHER
Intervention: Percutaneous Coronary Intervention of CTO
Description: CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
Study: NCT06298084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: 5.6 mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: 5.6 mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: 5.6 mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 100 mg b.i.d PO days 8-14 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 100 mg b.i.d PO days 8-14 every 21 days
Study: NCT05638165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
Study: NCT06593353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: SAIA an evidence-based, multi-prong, implementation strategy to improve systems thinking amongst frontline care teams to optimize care quality and continuity. The intervention includes monthly meetings where patient care cascades, process mapping and continuous quality improvement are used to identify bottlenecks and prioritize clinic based solutions.
Study: NCT06276322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low back pain group
Description: The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy group
Description: Low back pain kinematics compare them with asymptomatic kontrols
Study: NCT04634084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group(Bursa Implantation)
Description: Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group(Standard of Care)
Description: Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
Study: NCT06176261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.